Biopharmaceuticals Analyst Samimy, along with Dr. Peter Kaiser and Dr. David Eichenbaum, discuss geographic atrophy, relevant companies, APLS & ISEE–how will complement Inhibitors be incorporated and the expectations for Competitive Dynamics on an Analyst/Industry conference call to be held on February 21 at 2 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
- H.C. Wainwright says Belite Bio opportunity intact despite GA treatment approval
- Apellis price target raised to $115 from $79 at BofA
- Apellis price target raised to $75 from $65 at Stifel